What is COCP's market cap?

$19.46M, based on the Nov 4 close of $1.01.

Does Cocrystal Pharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of COCP is sold short?

179.2K shares, 1.9% of float, as of Oct 15, 2026.

What sector is COCP in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · COCPHealthcarePharmaceuticals

Cocrystal Pharma, Inc. Common Stock (COCP)

$1.01−5.61%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$1.06▼ 2.75% in range

Nov 3, 2025Low $0.82 · High $1.57Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Cocrystal Pharma closed at $1.01 on Nov 4, down 5.61%, 35.7% below its 52-week closing high. Volume of 22.8K shares was 0.65× its 20-day average (below normal).

Split-adjusted performance: -9.0% over one month, -28.4% over six months, -7.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $105K, with a net margin of -3013.3%.

Short interest was 179.2K shares at the Oct 15 settlement, up 2.3% from the prior report (1.9% of float, 4.9 days to cover).

Market cap$19.5M19.3M shares

Revenue · quarter$105.0K—

Diluted EPS$-0.23—

P/E · TTM—P/S 59.0×

Net margin-3,013.3%Gross 100.0%

Dividend yieldNone

52-week range0.82 – 1.57−35.7% from high

Volume22.8K0.65× 20-day avg

Volatility · 60d50.2%Annualised

Short % of float1.9%4.9 days to cover

Net cash$2.2MCash $2.2M

Next earnings—Not scheduled

Split-adjusted performance

1W +2.0%1M −9.0%3M −1.9%6M −28.4%YTD +3.2%1Y −7.3%3Y −37.8%5Y −90.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum47

Revenue growth—

Net margin10

Value (low P/E)—

Size21

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short179.2K+2.3% vs prior

Days to cover4.9Settled Oct 15

% of float1.9%

Short vol. 10d27.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
COCPCocrystal Pharma	$1.01	−5.61%	−28.4%	—	−3013.3%	—	$19.5M
IGCIGC Pharma	$0.1950	+4.84%	−38.7%	−19.2%	−1107.9%	—	$20.2M	Compare
CNTXContext Therapeutics	$0.2035	+4.90%	−91.6%	—	—	—	$18.7M	Compare
AYTUAYTU BioPharma	$1.92	−0.52%	−25.0%	+6.4%	−0.1%	—	$20.9M	Compare
EDSAEdesa Biotech	$2.17	−4.82%	−85.5%	—	—	—	$20.9M	Compare
MCRBSeres Therapeutics	$2.09	+6.63%	−73.9%	—	622.4%	—	$21.0M	Compare
TXMDTherapeuticsMD	$1.82	+2.25%	−10.3%	−8.7%	17.8%	—	$21.1M	Compare
ATOSAtossa Therapeutics	$2.12	−9.01%	−63.4%	—	—	—	$21.2M	Compare
KTTAPasithea Therapeutics	$0.5300	0.00%	−37.6%	—	—	—	$17.7M	Compare

News about Cocrystal Pharma

All news →

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewswire Inc. · May 15, 2026▲ Positive

Quick answers

What does Cocrystal Pharma do?: Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs.
What is COCP's market cap?: $19.46M, based on the Nov 4 close of $1.01.
Does Cocrystal Pharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of COCP is sold short?: 179.2K shares, 1.9% of float, as of Oct 15, 2026.
What sector is COCP in?: Healthcare, in the Pharmaceuticals industry.

About Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

HQ: Bothell, WA10 employeesListed Apr 1, 2008cocrystalpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology